FORTY SEVEN, INC.

FTSV NASDAQ
8.76
-1.36
-13.44%
盘后: 8.17 -0.59 -6.74% 19:48 07/17 EDT
开盘
9.39
昨收
10.12
最高
9.71
最低
8.73
成交量
83.86万
成交均量(3M)
22.88万
52周最高
23.83
52周最低
8.73
换手率
2.83%
市值
2.60亿
分时
5日
1月
3月
1年
5年

相关股票

微牛行情栏目提供FORTY SEVEN, INC. FTSV股票价格,FORTY SEVEN, INC.股票实时行情,公司简介,财报信息,股本结构等,掌握美港股行情走势,开盘价,收盘价,总市值,换手率,市盈率,收益率等数据,及时把握美股港股投资机会。

公司介绍

Forty Seven, Inc. is clinical-stage immuno-oncology company. The Company is focused on developing novel checkpoint therapies to activate macrophages in the fight against cancer. The Company’s lead product candidate, 5F9, is a humanized IgG4 subclass monoclonal antibody against CD47 that is designed to interfere with recognition of CD47 by the SIRPa receptor on macrophages. The Company’s another product FSI-189, is an antibody that binds to SIRPa and initiate Phase I solid tumor trials for FSI-189. The Company is investigating 5F9 in multiple Phase I and Phase II trials in various cancers including acute myeloid leukemia (AML), non-Hodgkin's lymphoma (NHL) and colorectal carcinoma (CRC), and ovarian cancer, as both a monotherapy and in combination with other therapies, such as rituximab and cetuximab. In addition to the 5F9, which is an antibody that binds to CD47 blocking its binding to SIRPa.
展开 >

最近浏览

名称
价格
涨跌幅